RxDoctor Payments Data

Jonathan Anderson, MD

Family Medicine · Fullerton, CANPI 1588664916

Payments from drug & device makers

$3,242in general payments, 2019–2025

Across 176 payments — averaging $18.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$565
  • Pfizer$473
  • GSK$298
  • Amgen$294
  • Novo Nordisk$200
  • Merck$172
  • plus $1K from 22 others

What the payments were for

  • Consulting fees$201%
  • Food & beverage$3,11996%
  • Education$1033%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,242 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$62,683
Medicare patients
224
Services billed
863

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban152$113,474
OzempicSemaglutide52$65,474
JardianceEmpagliflozin27$44,613
JanuviaSitagliptin Phosphate21$30,646
Repatha SureclickEvolocumab46$28,389
MounjaroTirzepatide18$21,181
Breo ElliptaFluticasone/Vilanterol30$20,790
Bydureon BciseExenatide Microspheres18$20,658
JanumetSitagliptin Phos/Metformin Hcl15$20,518
TradjentaLinagliptin13$19,349
Nurtec OdtRimegepant Sulfate11$18,794
Lantus SolostarInsulin Glargine,hum.Rec.Anlog47$7,297
Atorvastatin Calcium528$6,254
SymbicortBudesonide/Formoterol Fumarate20$6,157
SynthroidLevothyroxine Sodium39$4,435

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Nurtec Odt$473$132,269163 claims
Novo NordiskOzempic$200$65,47452 claims
Boehringer IngelheimJardiance, Tradjenta$126$63,96240 claims
MerckJanuvia, Janumet$172$51,16536 claims
Lilly USA, LLCMounjaro$123$21,18118 claims
GSKBreo Ellipta$298$20,79030 claims
AstraZenecaSymbicort$565$6,15720 claims
AbbVieSynthroid$142$4,43539 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.

Other family medicine in Fullerton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →